Key Points
- COO Michel Lagarde sold a total of 66,638 Thermo Fisher shares in recent trades (including 30,000 on Dec 2), totaling about $38.9 million and reducing his stake by roughly 50%.
- Thermo Fisher beat Q3 estimates with $5.79 EPS on $11.12 billion revenue and has set FY2025 guidance of 22.600–22.860 EPS (analysts expect ~23.28 EPS).
- The board authorized a $5 billion share buyback (up to ~2.4% of shares) and declared a quarterly dividend of $0.43 (annualized $1.72, yield ~0.3%), ex-dividend date Dec. 15.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) COO Michel Lagarde sold 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $581.92, for a total transaction of $17,457,600.00. Following the sale, the chief operating officer owned 29,480 shares of the company's stock, valued at approximately $17,155,001.60. The trade was a 50.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Michel Lagarde also recently made the following trade(s):
- On Wednesday, December 3rd, Michel Lagarde sold 32,000 shares of Thermo Fisher Scientific stock. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00.
- On Thursday, November 13th, Michel Lagarde sold 4,638 shares of Thermo Fisher Scientific stock. The stock was sold at an average price of $594.42, for a total value of $2,756,919.96.
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific stock opened at $574.76 on Friday. The firm has a market capitalization of $215.94 billion, a PE ratio of 33.20, a price-to-earnings-growth ratio of 4.24 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The firm's 50 day simple moving average is $557.53 and its 200 day simple moving average is $483.90. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the company earned $5.28 earnings per share. The firm's quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.94%.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on TMO shares. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating on the stock. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 25th. Argus increased their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a "buy" rating in a research note on Wednesday, October 29th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, UBS Group increased their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a "neutral" rating in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $602.35.
Read Our Latest Stock Report on TMO
Institutional Trading of Thermo Fisher Scientific
Several large investors have recently added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC raised its holdings in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares during the period. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth about $28,000. Highline Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific during the 1st quarter valued at approximately $30,000. Finally, Capital A Wealth Management LLC increased its stake in Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after acquiring an additional 66 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
